Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
Completed · Phase 3 · NCT03345914
Conditions: Dermatitis, Atopic
At a glance
- Research payments reported, 2025
- $6,712
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 367
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Dupilumab (drug), Matching Placebo (drug), Background Treatment: Topical Corticosteroids (other), Background Treatment: Moisturizers (other)
- Dates
- Started 2017-11-17; completion 2019-09-10
- Results posted
- Yes
The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to \<12 years of age with severe atopic dermatitis (AD). The secondary objective is to assess the safety of dupilumab administered concomitantly with TCS in patients ≥6 years to \<12 years of age with severe AD.
From ClinicalTrials.gov, last updated 2020-08-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $6,712 in research payments for this study in 2025 (15 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $6,712
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.